¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"restriction site"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • donor site
    Á¦°øºÎÀ§, °ø¿©ºÎÀ§
  • fragile site
    Ãë¾àºÎÀ§
  • ligand binding site
    ¸®°£µå°áÇÕºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • site
    ºÎÀ§
  • telomeric site
    ³¡ºÐÀýºÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • definitive site
    Âø»óºÎÀ§
  • donor site
    ÁִºÎÀ§, Á¦°øºÎÀ§
  • mutational site
    µ¹¿¬º¯À̺ÎÀ§
  • packaging site
    ²Ù¸®±âºÎÀ§
  • privileged site
    Ưº°°Ý¸®ºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • site
    ºÎÀ§
  • telomeric site
    ¸»´ÜºÎÀ§
  • web site
    À¥½ÎÀÌÆ®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • donor site
    ±Þ¿©ºÎ.
  • endonuclease, restriction
    Á¦ÇÑÈ¿¼Ò
  • enzyme, restriction
    Á¦ÇÑÈ¿¼Ò
  • fundic site
    ÀڱùٴÚÀÓ½Å
  • haplotype restriction
    ÁÖÁ¶Á÷ÀûÇÕÇ׿øº¹ÇÕü¿°»öü Â÷À̼ö¹Ý ¸é¿ªÁ¦ÇÑ
  • homologous restriction factor
    µ¿Á¾Á¦ÇÑÀÎÀÚ
  • internal ribosomal entry site (IRES)
    ³»ºÎ ¸®º¸¼Ø °áÇÕºÎÀ§
  • legal restriction
    ¹ýÀûÇѰè(¡­ùÚÍ£).
  • legal restriction
    ¹ýÀûÇѰè(ÊṴ̀˭).
  • mst ii restriction enzyme
    Mst II Á¦ÇÑÈ¿¼Ò(¡­ ð¤ùÚý£áÈ)
  • mutational site
    (µ¹¿¬)º¯ÀÌÁ¡.
  • packaging site
    ²Ù¸®±âºÎÀ§
  • placental site trophoblastic tumor
    ŹݺÎÂøºÎÀ§ À¶¸ð»óÇǼºÁ¾¾ç
  • privileged site
    Ưº°°Ý¸®ºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • restriction polymorphism
    Á¦ÇÑ ´ÙÇü¼º(Òýúþàõ)
  • acceptor site
    ¼ö¿ëºÎÀ§ (â¥é»Ý»êÈ)
  • active site
    Ȱ¼º(üÀàõ)ÀÚ¸®
  • active site-directed irreversible inhibitor
    Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
  • alternate-site model
    ±³´ëºÎÀ§(ÎßÓÛÝ»êÈ)¸ðÅÚ
  • amino acid attachement site
    ¾Æ¹Ì³ë»ê(ß«) ºÎÂø(ݾó·)ÀÚ¸®
  • aminoacyl site
    ¾Æ¹Ì³ë¾Æ½Ç ÀÚ¸®
  • aminoacyl-tRNA site
    ¾Æ¹Ì³ë¾Æ½ÇtRNA ÀÚ¸®
  • antibody combining site
    Ç×ü°áÂø(ù÷ô÷Ì¿ó·)ÀÚ¸®
  • antigen binding site
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê)ÀÚ¸®
  • AP site
    AP ÀÚ¸®
  • A-site
    AÀÚ¸®
  • attachment site
    ºÎÂø(ݾó·)ÀÚ¸®
  • binding site
    °áÇÕ(Ì¿ùê)ÀÚ¸®
  • catalytic site
    Ã˸Å(õºØÚ)ÀÚ¸®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RELV restriction fragment length variant
RFLP restriction fragment length polymorphism
GnRH Gonadotropin Releasing Hormone  [HP 1898, 2034]
  = LHRH
  = Go...
CMS children's medical services; Christian Medical Society; chronic myelodysplastic syndrome; chromosome...
DABP D site albumin promoter binding protein
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CR Caloric restriction
DR Diet restriction
DR Dietary restriction
ER Energy restriction
FGR Fetal growth restriction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • surgical site
    ¼ö¼ú ºÎÀ§
  • web site
    À¥½ÎÀÌÆ®
    ÀÎÅͳݿ¡¼­ ¾î¶² Á¤º¸¸¦ Á¦°øÇϰí ÀÖ´Â ÇϳªÀÇ »çÀ̹ö °ø°£. ÀÎÅÍ³Ý ÁÖ¼Ò°¡ °¡¸®Å°´Â °÷.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
host restriction-modification A bacterial system where the bacterium is able to destroy invading DNA from a bacteriophage (virus which infects bacteria) while at the same time preventing the destruction of their own DNA. The phage DNA is cleaved by a restriction enzyme made by the bacterium, the bacterial DNA is modified (usually with methylation) so that the enzyme will not destroy it.
(09 Oct 1997)
DNA restriction enzymes <enzyme> Enzymes that are part of the restriction-modification systems. They catalyze the endonucleolytic cleavage of DNA sequences which lack the species-specific methylation pattern in the host cell's DNA. Cleavage yields random or specific double-stranded fragments with terminal 5'-phosphates. The function of restriction enzymes is to destroy any foreign DNA that invades the host cell. most have been studied in bacterial systems, but a few have been found in eukaryotic organisms. They are also used as tools for the systematic dissection and mapping of chromosomes, in the determination of base sequences of dnas, and have made it possible to splice and recombine genes from one organism into the genome of another.
Registry number: EC 3.1.21
(12 Dec 1998)
DNA restriction-modification enzymes Systems consisting of two enzymes, a modification methylase and a restriction endonuclease. They are closely related in their specificity and protect the DNA of a given bacterial species. The methylase adds methyl groups to adenine or cytosine residues in the same target sequence that constitutes the restriction enzyme binding site. The methylation renders the target site resistant to restriction, thereby protecting DNA against cleavage.
(12 Dec 1998)
ecori restriction enzyme <enzyme, molecular biology> A commonly-used restriction enzyme (enzyme which will cleave the phosphodiester bonds of DNA at specific nucleotide sequences) that came from the bacteria Escherichia coli and recognises the sequence GAATTC.
The enzyme will make a staggered cut of the double-stranded DNA molecule by cutting between the G and A on both strands.
(09 Oct 1997)
lactase restriction An inherited trait in which there is low lactase activity and thus there is defective lactose intestinal metabolism.
Compare: lactase persistence.
(05 Mar 2000)
acceptor site The ribosomal binding site for the aminoacyl-tRNA during protein synthesis.
(05 Mar 2000)
acceptor splicing site Boundary between the right end of an intron and the left end of the adjacent exon.
Synonym: acceptor splicing site.
(05 Mar 2000)
active site <chemistry> A specific region of an enzyme where a substrate binds and catalysis takes place (binding site).
(06 May 1997)
allosteric site A specific site on a multi-subunit enzyme or other protein that is not the substrate binding site, but that when reversibly bound by an effector, induces a conformational change in the protein, altering its catalytic or binding properties.
(12 Dec 1998)
amidation site <molecular biology> A C terminus consensus sequence, required for C terminus amidation of peptides. Consensus is glycine, followed by 2 basic amino acids (arg or lys).
(18 Nov 1997)
antibody combining site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-combining site See: paratope.
(05 Mar 2000)
apurinic site <molecular biology> Sites in DNA from which purines have been lost by cleavage of the deoxy ribose N glycosidic linkage.
(18 Nov 1997)
apyrimidinic site <molecular biology> A site on DNA where a base is missing, in this case a pyrimidine (either cytosine or thymine), but the phosphodiester backbone is still intact.
Compare: apurinic site.
(09 Oct 1997)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
restriction site The specific DNA sequence to which a restriction enzyme binds. Also called recognition site or recognition sequence.
Ãâó: www.promega.com/techserv/apps/hmnid/referenceinfor...
restriction site The specific nucleotide sequence of DNA at which a particular restriction enzyme cuts the DNA.
Ãâó: www.ipgri.cgiar.org/training/unit10-1-4/glossary.h...
restriction site restric
Ãâó: www.allwords.com/glossaryPage.php
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á